Academic Journal
Oncological outcomes in fertility-sparing treatment in stage IA-G2 endometrial cancer
| العنوان: | Oncological outcomes in fertility-sparing treatment in stage IA-G2 endometrial cancer |
|---|---|
| المؤلفون: | Ronsini C., Mosca L., Iavarone I., Nicoletti R., Vinci D., Carotenuto R. M., Pasanisi F., Solazzo M. C., De Franciscis P., Torella M., La Verde M., Colacurci N., Cobellis L., Vizzielli G., Restaino S. |
| المساهمون: | Ronsini, C., Mosca, L., Iavarone, I., Nicoletti, R., Vinci, D., Carotenuto, R. M., Pasanisi, F., Solazzo, M. C., De Franciscis, P., Torella, M., La Verde, M., Colacurci, N., Cobellis, L., Vizzielli, G., Restaino, S. |
| سنة النشر: | 2022 |
| المجموعة: | Università degli Studi di Udine: CINECA IRIS |
| مصطلحات موضوعية: | endometrial cancer, fertility, levonorgestrel intrauterine device (IUD), medroxyprogesterone acetate, pregnancy outcomes |
| الوصف: | Background: The gold standard treatment for early-stage endometrial cancer (EC) is hysterectomy with bilateral salpingo-oophorectomy (BSO) with lymphadenectomy. In selected patients desiring pregnancy, fertility-sparing treatment (FST) can be adopted. Our review aims to collect the most incisive studies about the possibility of conservative management for patients with grade 2, stage IA EC. Different approaches can be considered beyond demolition surgery, such as local treatment with levonorgestrel-releasing intra-uterine device (LNG-IUD) plus systemic therapy with progestins. Study design: Our systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. PubMed, EMBASE, and Scopus databases were consulted, and five studies were chosen based on the following criteria: patients with a histological diagnosis of EC stage IA G2 in reproductive age desiring pregnancy and at least one oncological outcome evaluated. Search imputes were “endometrial cancer” AND “fertility sparing” AND “oncologic outcomes” AND “G2 or stage IA”. Results: A total of 103 patients were included and treated with a combination of LNG-IUD plus megestrol acetate (MA) or medroxyprogesterone acetate (MPA), gonadotrophin-releasing hormone (GnRH) plus MPA/MA, hysteroscopic resectoscope (HR), and dilation and curettage (D&C). There is evidence of 70% to 85% complete response after second-round therapy prolongation to 12 months. Conclusions: Conservative measures must be considered temporary to allow pregnancy and subsequently perform specific counseling to adopt surgery. Fertility-sparing management is not the current standard of care for young women with EC. It can be employed for patients with early-stage diseases motivated to maintain reproductive function. Indeed, the results are encouraging, but the sample size must be increased. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/wos/WOS:000862726300001; volume:12; journal:FRONTIERS IN ONCOLOGY; https://hdl.handle.net/11390/1236225; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85139127022 |
| DOI: | 10.3389/fonc.2022.965029 |
| الاتاحة: | https://hdl.handle.net/11390/1236225 https://doi.org/10.3389/fonc.2022.965029 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.DDA3174C |
| قاعدة البيانات: | BASE |
| DOI: | 10.3389/fonc.2022.965029 |
|---|